WuXi Biologics reduces issued share capital by 22.5m shares in October

WuXi Biologics (Cayman) Inc. announced a net reduction in its total issued shares for the month ended 31 October 2025, with the total number of issued shares decreasing from 4,087,867,673 to 4,065,352,254. This change reflects a decrease of 22,515,419 shares. The reduction was largely attributed to the repurchase and cancellation of 23,180,000 ordinary shares on 16 October 2025 at a price of HK$25.75 per share, previously repurchased on 8 July and 9 July 2025.

In contrast to the overall decrease, the company saw an increase in issued shares through the exercise of Pre-IPO Share Options, adding 664,581 ordinary shares. The total funds raised from these exercises amounted to $133,695.94. The company confirmed that no further share options could be granted under the Pre-IPO Share Option Scheme since the listing date.

The authorized/registered share capital remained stable at 6,000,000,000 ordinary shares with a par value of $0.000008333333, totaling $50,000. There were no movements in treasury shares during the month. The company also confirmed compliance with all relevant listing rules and legal requirements concerning the reported movements.